294 related articles for article (PubMed ID: 31351210)
1. Rechallenging Recurrent Glioblastoma with Intra-Arterial Bevacizumab with Blood Brain-Barrier Disruption Results in Radiographic Response.
Faltings L; Kulason KO; Patel NV; Wong T; Fralin S; Li M; Schneider JR; Filippi CG; Langer DJ; Ortiz R; Boockvar JA
World Neurosurg; 2019 Nov; 131():234-241. PubMed ID: 31351210
[TBL] [Abstract][Full Text] [Related]
2. Durability of single dose intra-arterial bevacizumab after blood/brain barrier disruption for recurrent glioblastoma.
Chakraborty S; Filippi CG; Burkhardt JK; Fralin S; Ray A; Wong T; Ortiz R; Langer DJ; Boockvar JA
J Exp Ther Oncol; 2016 Nov; 11(4):261-267. PubMed ID: 27849336
[TBL] [Abstract][Full Text] [Related]
3. Intra-arterial delivery of bevacizumab after blood-brain barrier disruption for the treatment of recurrent glioblastoma: progression-free survival and overall survival.
Burkhardt JK; Riina H; Shin BJ; Christos P; Kesavabhotla K; Hofstetter CP; Tsiouris AJ; Boockvar JA
World Neurosurg; 2012 Jan; 77(1):130-4. PubMed ID: 22405392
[TBL] [Abstract][Full Text] [Related]
4. Superselective intraarterial cerebral infusion of cetuximab with blood brain barrier disruption combined with Stupp Protocol for newly diagnosed glioblastoma.
Kulason KO; Schneider JR; Chakraborty S; Filippi CG; Pramanik B; Wong T; Fralin S; Tan K; Ray A; Alter RA; Ortiz R; Demopoulos A; Langer DJ; Boockvar JA
J Exp Ther Oncol; 2018 May; 12(3):223-229. PubMed ID: 29790314
[TBL] [Abstract][Full Text] [Related]
5. Apparent diffusion coefficient changes predict survival after intra-arterial bevacizumab treatment in recurrent glioblastoma.
Galla N; Chiang G; Chakraborty S; Singh R; John Tsiouris A; Boockvar J; Kovanlikaya I
Neuroradiology; 2017 May; 59(5):499-505. PubMed ID: 28343250
[TBL] [Abstract][Full Text] [Related]
6. Long-term benefit of intra-arterial bevacizumab for recurrent glioblastoma.
Alter RA; White TG; Fanous AA; Chakraborty S; Filippi CG; Pisapia DJ; Tsiouris AJ; Boockvar JA
J Exp Ther Oncol; 2017 May; 12(1):67-71. PubMed ID: 28472567
[TBL] [Abstract][Full Text] [Related]
7. Repeated superselective intraarterial bevacizumab after blood brain barrier disruption for newly diagnosed glioblastoma: a phase I/II clinical trial.
Patel NV; Wong T; Fralin SR; Li M; McKeown A; Gruber D; D'Amico RS; Patsalides A; Tsiouris A; Stefanov DG; Flores O; Zlochower A; Filippi CG; Ortiz R; Langer DJ; Boockvar JA
J Neurooncol; 2021 Nov; 155(2):117-124. PubMed ID: 34601657
[TBL] [Abstract][Full Text] [Related]
8. Intraarterial delivery of bevacizumab and cetuximab utilizing blood-brain barrier disruption in children with high-grade glioma and diffuse intrinsic pontine glioma: results of a phase I trial.
McCrea HJ; Ivanidze J; O'Connor A; Hersh EH; Boockvar JA; Gobin YP; Knopman J; Greenfield JP
J Neurosurg Pediatr; 2021 Aug; 28(4):371-379. PubMed ID: 34359048
[TBL] [Abstract][Full Text] [Related]
9. Safety and maximum tolerated dose of superselective intraarterial cerebral infusion of bevacizumab after osmotic blood-brain barrier disruption for recurrent malignant glioma. Clinical article.
Boockvar JA; Tsiouris AJ; Hofstetter CP; Kovanlikaya I; Fralin S; Kesavabhotla K; Seedial SM; Pannullo SC; Schwartz TH; Stieg P; Zimmerman RD; Knopman J; Scheff RJ; Christos P; Vallabhajosula S; Riina HA
J Neurosurg; 2011 Mar; 114(3):624-32. PubMed ID: 20964595
[TBL] [Abstract][Full Text] [Related]
10. Republished: Real-time MRI guidance for intra-arterial drug delivery in a patient with a brain tumor: technical note.
Zawadzki M; Walecki J; Kostkiewicz B; Kostyra K; Pearl MS; Solaiyappan M; Walczak P; Janowski M
J Neurointerv Surg; 2019 Aug; 11(8):e3. PubMed ID: 31123186
[TBL] [Abstract][Full Text] [Related]
11. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
12. Superselective intraarterial cerebral infusion of cetuximab after osmotic blood/brain barrier disruption for recurrent malignant glioma: phase I study.
Chakraborty S; Filippi CG; Wong T; Ray A; Fralin S; Tsiouris AJ; Praminick B; Demopoulos A; McCrea HJ; Bodhinayake I; Ortiz R; Langer DJ; Boockvar JA
J Neurooncol; 2016 Jul; 128(3):405-15. PubMed ID: 26945581
[TBL] [Abstract][Full Text] [Related]
13. Superselective intraarterial cerebral infusion of bevacizumab: a revival of interventional neuro-oncology for malignant glioma.
Riina HA; Fraser JF; Fralin S; Knopman J; Scheff RJ; Boockvar JA
J Exp Ther Oncol; 2009; 8(2):145-50. PubMed ID: 20192120
[TBL] [Abstract][Full Text] [Related]
14. The added value of bevacizumab concomitantly administered with carboplatin versus carboplatin alone in patients with recurrent glioblastomas.
Kaloshi G; Diamandi P; Cakani B; Brace G; Rroji A; Petrela M
Tumori; 2015; 101(1):41-5. PubMed ID: 25702676
[TBL] [Abstract][Full Text] [Related]
15. Cerebral blood volume and apparent diffusion coefficient - Valuable predictors of non-response to bevacizumab treatment in patients with recurrent glioblastoma.
Petrova L; Korfiatis P; Petr O; LaChance DH; Parney I; Buckner JC; Erickson BJ
J Neurol Sci; 2019 Oct; 405():116433. PubMed ID: 31476621
[TBL] [Abstract][Full Text] [Related]
16. Bevacizumab in combination with radiotherapy and temozolomide for patients with newly diagnosed glioblastoma multiforme.
van Linde ME; Verhoeff JJ; Richel DJ; van Furth WR; Reijneveld JC; Verheul HM; Stalpers LJ
Oncologist; 2015 Feb; 20(2):107-8. PubMed ID: 25582142
[TBL] [Abstract][Full Text] [Related]
17. Afatinib, an irreversible ErbB family blocker, with protracted temozolomide in recurrent glioblastoma: a case report.
Alshami J; Guiot MC; Owen S; Kavan P; Gibson N; Solca F; Cseh A; Reardon DA; Muanza T
Oncotarget; 2015 Oct; 6(32):34030-7. PubMed ID: 26423602
[TBL] [Abstract][Full Text] [Related]
18. Advantages and Disadvantages of Combined Chemotherapy with Carmustine Wafer and Bevacizumab in Patients with Newly Diagnosed Glioblastoma: A Single-Institutional Experience.
Akiyama Y; Kimura Y; Enatsu R; Mikami T; Wanibuchi M; Mikuni N
World Neurosurg; 2018 May; 113():e508-e514. PubMed ID: 29476996
[TBL] [Abstract][Full Text] [Related]
19. Single-agent Bevacizumab in Recurrent Glioblastoma After Second-line Chemotherapy With Fotemustine: The Experience of the Italian Association of Neuro-Oncology.
Pasqualetti F; Pace A; Gonnelli A; Villani V; Cantarella M; Delishaj D; Vivaldi C; Molinari A; Montrone S; Pellerino A; Franchino F; Baldaccini D; Lombardi G; Lolli I; Catania F; Bazzoli E; Morganti R; Fabi A; Zagonel V; Bocci G; Fabrini MG; Rudà R; Soffietti R; Paiar F
Am J Clin Oncol; 2018 Dec; 41(12):1272-1275. PubMed ID: 29782366
[TBL] [Abstract][Full Text] [Related]
20. Metabolic response of glioblastoma to superselective intra-arterial cerebral infusion of bevacizumab: a proton MR spectroscopic imaging study.
Jeon JY; Kovanlikaya I; Boockvar JA; Mao X; Shin B; K Burkhardt J; Kesavabhotla K; Christos P; Riina H; Shungu DC; Tsiouris AJ
AJNR Am J Neuroradiol; 2012 Dec; 33(11):2095-102. PubMed ID: 22576886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
